Gyre Therapeutics to Buy Cullgen, Which Ends Merger With Pulmatrix

Dow Jones03-02

By Colin Kellaher

Gyre Therapeutics has agreed to buy privately held, clinical-stage biopharmaceutical company Cullgen in an all-stock transaction valued at about $300 million, upending plans by Pulmatrix to merge with Cullgen.

Gyre on Monday said the acquisition of Cullgen will create a U.S.- and China-based fully integrated biopharmaceutical company with revenue-producing commercial assets and a pipeline of degraders, targeting inflammatory diseases and cancers.

San Diego-based Gyre said it expects to complete the acquisition early in the second quarter.

Pulmatrix, a Framingham, Mass., biopharmaceutical company, in late 2024 agreed to merge with China-based Cullgen, but the deal encountered regulatory delays in China, and Pulmatrix on Monday said Cullgen had terminated the agreement.

Pulmatrix said it has been working to identify an alternative reverse merger opportunity, adding that it is encouraged by the interest it has received and a recent increase in deal activity within its industry.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

March 02, 2026 10:23 ET (15:23 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2616020356?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-02 23:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616020356","market":"sh","top_or_hot":-1,"title":"Gyre Therapeutics to Buy Cullgen, Which Ends Merger With Pulmatrix","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/GYRE\">Gyre Therapeutics</a> has agreed to buy privately held, clinical-stage biopharmaceutical company Cullgen in an all-stock transaction valued at about $300 million, upending plans by Pulmatrix to merge with Cullgen. \n</p>\n<p>\n  Gyre on Monday said the acquisition of Cullgen will create a U.S.- and China-based fully integrated biopharmaceutical company with revenue-producing commercial assets and a pipeline of degraders, targeting inflammatory diseases and cancers. \n</p>\n<p>\n  San Diego-based Gyre said it expects to complete the acquisition early in the second quarter. \n</p>\n<p>\n  Pulmatrix, a Framingham, Mass., biopharmaceutical company, in late 2024 agreed to merge with China-based Cullgen, but the deal encountered regulatory delays in China, and Pulmatrix on Monday said Cullgen had terminated the agreement. \n</p>\n<p>\n  Pulmatrix said it has been working to identify an alternative reverse merger opportunity, adding that it is encouraged by the interest it has received and a recent increase in deal activity within its industry. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 02, 2026 10:23 ET (15:23 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gyre Therapeutics to Buy Cullgen, Which Ends Merger With Pulmatrix</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGyre Therapeutics to Buy Cullgen, Which Ends Merger With Pulmatrix\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-03-02 23:23</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/GYRE\">Gyre Therapeutics</a> has agreed to buy privately held, clinical-stage biopharmaceutical company Cullgen in an all-stock transaction valued at about $300 million, upending plans by Pulmatrix to merge with Cullgen. \n</p>\n<p>\n  Gyre on Monday said the acquisition of Cullgen will create a U.S.- and China-based fully integrated biopharmaceutical company with revenue-producing commercial assets and a pipeline of degraders, targeting inflammatory diseases and cancers. \n</p>\n<p>\n  San Diego-based Gyre said it expects to complete the acquisition early in the second quarter. \n</p>\n<p>\n  Pulmatrix, a Framingham, Mass., biopharmaceutical company, in late 2024 agreed to merge with China-based Cullgen, but the deal encountered regulatory delays in China, and Pulmatrix on Monday said Cullgen had terminated the agreement. \n</p>\n<p>\n  Pulmatrix said it has been working to identify an alternative reverse merger opportunity, adding that it is encouraged by the interest it has received and a recent increase in deal activity within its industry. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 02, 2026 10:23 ET (15:23 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2616020356","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2616020356","pubTimestamp":1772464980,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Gyre Therapeutics has agreed to buy privately held, clinical-stage biopharmaceutical company Cullgen in an all-stock transaction valued at about $300 million, upending plans by Pulmatrix to merge with Cullgen.Gyre on Monday said the acquisition of Cullgen will create a U.S.- and China-based fully integrated biopharmaceutical company with revenue-producing commercial assets and a pipeline of degraders, targeting inflammatory diseases and cancers.San Diego-based Gyre said it expects to complete the acquisition early in the second quarter.Pulmatrix, a Framingham, Mass., biopharmaceutical company, in late 2024 agreed to merge with China-based Cullgen, but the deal encountered regulatory delays in China, and Pulmatrix on Monday said Cullgen had terminated the agreement.Pulmatrix said it has been working to identify an alternative reverse merger opportunity, adding that it is encouraged by the interest it has received and a recent increase in deal activity within its industry.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","PULM":"Pulmatrix, Inc.","GYRE":"Gyre Therapeutics","BK4139":"生物科技"},"translate_title":"Gyre Therapeutics收购Cullgen，结束与Pulmatrix的合并","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GYRE":1.5,"PULM":1.5},"content_text":"By Colin Kellaher \n\n\n \n\n\nGyre Therapeutics has agreed to buy privately held, clinical-stage biopharmaceutical company Cullgen in an all-stock transaction valued at about $300 million, upending plans by Pulmatrix to merge with Cullgen. \n\n\n  Gyre on Monday said the acquisition of Cullgen will create a U.S.- and China-based fully integrated biopharmaceutical company with revenue-producing commercial assets and a pipeline of degraders, targeting inflammatory diseases and cancers. \n\n\n  San Diego-based Gyre said it expects to complete the acquisition early in the second quarter. \n\n\n  Pulmatrix, a Framingham, Mass., biopharmaceutical company, in late 2024 agreed to merge with China-based Cullgen, but the deal encountered regulatory delays in China, and Pulmatrix on Monday said Cullgen had terminated the agreement. \n\n\n  Pulmatrix said it has been working to identify an alternative reverse merger opportunity, adding that it is encouraged by the interest it has received and a recent increase in deal activity within its industry. \n\n\n \n\n\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 02, 2026 10:23 ET (15:23 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2616020356","isCrawlerRequest":true}